Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing

Adv Healthc Mater. 2015 Jun 3;4(8):1180-9. doi: 10.1002/adhm.201500089. Epub 2015 Apr 11.

Abstract

Adoptive T cell immunotherapy is a promising treatment strategy for epithelial ovarian cancer (EOC). However, programmed death ligand-1 (PD-L1), highly expressed on EOC cells, interacts with programmed death-1 (PD-1), expressed on T cells, causing immunosuppression. This study aims to block PD-1/PD-L1 interactions by delivering PD-L1 siRNA, using various folic acid (FA)-functionalized polyethylenimine (PEI) polymers, to SKOV-3-Luc EOC cells, and investigate the sensitization of the EOC cells to T cell killing. To enhance siRNA uptake into EOC cells, which over express folate receptors, PEI is modified with FA or PEG-FA so that siRNA is complexed into nanoparticles with folate molecules on the surface. PEI modification with a single functional group lowers the polymer cytotoxicity compared to unmodified PEI. FA-conjugated polymers increase siRNA uptake into SKOV-3-luc cells and decrease unspecific uptake into monocytes. All polymers result in 40% to 50% PD-L1 protein knockdown. Importantly, SKOV-3-Luc cells treated with either PEI-FA or PEI- polyethylene glycol (PEG)-FA/PD-L1 siRNA complexes are up to twofold more sensitive to T cell killing compared to scrambled siRNA treated controls. These findings are the first to demonstrate that PD-L1 knockdown in EOC cells, via siRNA/FA-targeted delivery, are able to sensitize cancer cells to T cell killing.

Keywords: PD-L1 knock-down; T cells; ovarian cancer; polyethylenimine; siRNA delivery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / genetics*
  • B7-H1 Antigen / metabolism
  • Carcinoma, Ovarian Epithelial
  • Cell Line, Tumor
  • Down-Regulation
  • Female
  • Folic Acid / metabolism*
  • Gene Expression Regulation, Neoplastic*
  • Genetic Therapy
  • Humans
  • Immunotherapy / methods
  • Lysosomal-Associated Membrane Protein 1 / genetics
  • Lysosomal-Associated Membrane Protein 1 / metabolism
  • Nanoparticles / chemistry
  • Neoplasms, Glandular and Epithelial / genetics*
  • Neoplasms, Glandular and Epithelial / therapy
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / therapy
  • Particle Size
  • Polyethylene Glycols / chemistry
  • Polyethyleneimine / metabolism*
  • Polymers / chemistry
  • RNA, Small Interfering / genetics*
  • T-Lymphocytes / metabolism

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • Lysosomal-Associated Membrane Protein 1
  • Polymers
  • RNA, Small Interfering
  • Polyethylene Glycols
  • Polyethyleneimine
  • Folic Acid